By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
News for IndiaNews for IndiaNews for India
  • Home
  • Posts
  • Search Page
  • About us
Reading: Zydus Wellness Q3 Review: Anand Rathi Stays ‘Buy’ Despite Mixed Numbers — Check Revised Target Price
Share
Font ResizerAa
News for IndiaNews for India
Font ResizerAa
  • Economics
  • Business
  • Home
  • Categories
    • Business
    • Economics
  • About us
  • Sitemap
Follow US
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
News for India > Business > Zydus Wellness Q3 Review: Anand Rathi Stays ‘Buy’ Despite Mixed Numbers — Check Revised Target Price
Business

Zydus Wellness Q3 Review: Anand Rathi Stays ‘Buy’ Despite Mixed Numbers — Check Revised Target Price

Last updated: February 4, 2026 1:00 pm
3 months ago
Share
SHARE



NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Zydus Wellness Ltd. delivered a mixed set of numbers in Q3 FY26, with healthy double-digit organic volume growth driving revenue to Rs 960 crore (vs Rs 820 crore street estimate), while Ebitda stood at Rs 61 crore (vs estimate of Rs 68.5 crore).

Comfort Click performed in-line with the management’s expectations, while Ritebite Maxprotein outperformed. Its focus on innovation, brand extension and leveraging distribution is likely to lead to healthy volume-led growth, going forward. Further, the management exuded confidence in achieving 16/17% consolidated Ebitda margin in the coming year with more than 14% margin in Comfort Click.

Anand Rathi trims its earnings estimate by 18-36% over FY25-28e to factor in weaker margin and higher amortisation expenses for Comfort Click acquisition. Nonetheless, remaining positive on the company’s growth prospects, the brokerage maintains Buy rating on the stock with a 12-month target price of Rs 525 (from Rs 599 earlier), valuing it at 30 times FY28e earnings per share (from 30x Sep’27e EPS previously).

Click on the attachment to read the full report:

Anand Rathi Zydus Wellness Q3fy26 Results Review.pdf

VIEW DOCUMENT

Also Read: AWL Agri Shares May Rally 40% Says ICICI Securities After Q3 Results — Check Target Price

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

 

Comprehensive Budget 2026 coverage,
LIVE TV analysis,
Stock Market and
Industry reactions,
Income Tax changes and
Latest News on NDTV Profit.




Source link

You Might Also Like

Access Denied

Access Denied

Access Denied

Access Denied

Access Denied

TAGGED:Zydus Wellness Ltd. (Stock)
Share This Article
Facebook Twitter Email Print
Previous Article India Safeguarded Interests Of Farmers, Dairy Producers In US Trade Deal: Piyush Goyal
Next Article Oppo K14x Camera, Display, Battery, Other Specs Confirmed Ahead Of Feb. 10 Launch

We influence 20 million users and is the number one business and technology news network on the planet.

Find Us on Socials

News for IndiaNews for India
© Wealth Wave Designed by Preet Patel. All Rights Reserved.
  • BUSINESS